PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no per

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 10/559,929

Filing Date May 2, 2006

First Named Inventor Peter LONAI Z"L

Art Unit 1632

Examiner Name Not Yet available

30800 Attorney Docket Number of Sheet **U.S. PATENT DOCUMENTS** Name of Patentee or Pages, Columns, Lines, Where Document Number Publication Date Examiner DD-MMM-YYYY Relevant Passages or Relevant Applicant of Cited Document Initials* Figures Appear Number-Kind Code^{2 (if known)} US-5,274,125 02-Apr-1966 Heinrich 2 US-5,843,780 01-Dec-1998 Thomson 03-Aug-1999 Siegall 3 US-5,932,447 18-Jul-2000 Gearhart et al. US-6,090,622 4 FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Examiner Cite **Publication Date** Name of Patentee or Foreign Patent Documents Initials* Where Relevant Passages DD-MMM-YYYY Applicant of Cited Document or Relevant Figures Appear Country Code3- Number4- Kind Code5 (if known)

Examiner Signature					Date Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EER 07 2008

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons at

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known
Application Number 10/559,929
Filing Date May 2, 2006
First Named Inventor Peter LONAI Z"L
Group Art Unit 1632
Examiner Name Not Yet available

										. a variable	
Sheet		2	Of		6		Attorney Docket Nu		30800		
							LITERATURE				
Examiner	Cite						, title of the article (v				
Initials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
	5	Adra et al. "Cloning and Expression of the Mouse PGK-1 Gene and the Nucleotide									
					Gene, 60:			che and th	c ivacic	onde	
	6						yonic Stem Cell	Lines Mai	ntain		
	1						Prolonged Period				
		Developm							•		
	7	Ballas et al. "Adult Bone Marrow Stem Cells for Cell and Gene Therapies: Implications for Greater Use", Journal of Cellular Biochemistry Supplement, 38:									
		20-28, 2002.									
	8	Belting "Heparan Sulfate Proteoglycan as A Plasma Membrane Carrier", Trends in									
		Biochemic									
	9						es fro Central Ne	rvous Sys	tem		
							-544, 2000.				
	10	Bongso et al. "Improved Quality of Human Embryos When Co-Cultured With									
		Human Ampullary Cells", Human Reproduction, 4(6): 706-713, 1989.									
	11	Brisson et al. "Expression of A Bacterial Gene in Plants by Using A Viral Vector",							ctor",		
		Nature, 31									
	12	Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", 224: 838-843, 1984.									
	1	Carboxyla	se Small	Subunit	Gene in T	ransfo	ormed Plant Cells	", 224: 83	<u>8-843,</u>	1984.	
	13	Chen et al. "Fibroblast Growth Factor (FGF) Signaling Through PI 3-Kinase and Akt/PKB Is Required for Embryoid Body Differentiation", Oncogene, 19: 3750-								ind	
				ed for E	mbryoid B	lody L	Offerentiation", C	Incogene,	19: 375	60-	
	14	3756, 2000		C	:C 1 T :	ala n	1.4.15	C D	N. 1		
	14						egulated Expressi				
		Gene Encoding the Small Subunit of Ribulose-1,5-Bisphosphate Carboxylase", The EMBO Journal, 3(8): 1671-1679, 1984.									
	15						minal A True Ca	on Maska	C-	_	
	13	Coucouvanis et al. Signals for Death and Survival: A Two-Step Mechanism for								r	
	16	Cavitation in the Vertebrate Embryo", Cell, 83: 279-287, 1995. Doetschman et al. "Establishment of Hamster Blastocyst-Derived Embryonic Stem								Stom	
	10	(ES) Cells", Developmental Biology, 127: 224-227, 1988.									
	17	Ekblom et al. "Expression and Biological Role of Laminin-1", Matrix Biology, 22:								22.	
	1	35-47, 2003.									
	18	Farrell et al. "Secretion of Cytoplasmic and Nuclear Proteins From Animal Cells									_
		Using Nov	el Secret	ion Mod	lules". Prot	teins	Structure, Function	on, and Ge	enetics	41.	
		Using Novel Secretion Modules", Proteins: Structure, Function, and Genetics, 41: 144-153, 2000.									
Examiner		<u> </u>						Date			
Signature	1							Considere	4		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/559,929 INFORMATION DISCLOSURE Filing Date May 2, 2006 STATEMENT BY APPLICANT Peter LONAI Z"L First Named Inventor Art Unit 1632 (use as many sheets as necessary) Not Yet available **Examiner Name** Attorney Docket Number Sheet Of OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner Initials* item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T² publisher, city and/or country where published. 19 Felgner "Particulate Systems and Polymers for In Vitro and In Vivo Delivery of Polynucleotides", Advanced Drug Delivery Reviews, 5: 163-187, 1990. Felgner et al. "Cationic Liposome-Mediated Transfection", Nature, 337: 387-388, 20 Felgner et al. "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection 21 Procedure", Proc. Natl. Acad. Sci. USA, 84: 7413-7417, 1987. 22 Fujikura et al. "Differentiation of Embryonic Stem Cells Is Induced by GATA Factors", Genes & Development, 16: 784-789, 2002. Gardner et al. "Culture and Transfer of Human Blastcysts Increases Implantation 23 Rates and Reduces the Need for Multiple Embryo Transfers", Fertility and Sterility, 69(1): 84-88, 1998. Giles et al. "Pluripotency of Cultured Rabbit Inner Cell Mass Cells Detected by 24 Isozyme Analysis and Eye Pigmentation of Fetuses Following Injection Into Blastocysts of Morulae", Molecular Reproduction and Development", 36: 130-138, 25 Graves et al. "Derivation and Characterization of Putative Pluripotential Embryonic Stem Cells From Preimplantation Rabbit Embryos", Molecular Reproduction and Development, 36: 424-433, 1993. Gurley et al. "Upstream Sequences Required for Efficient Expression of A Soybean 26 Heat Shock Gene", Molecular and Cellular Biology, 6(2): 559-565, 1986. 27 Horikawa et al. "Cloning and Characterization of the Promoter Region of Human Telomerase", Cancer Research, 59: 826-830, 1999. Hutvágner et al. "RNAi: Nature Abhors A Double-Strand", Current Opinion in 28 Genetics & Development, 12: 225-232, 2002. Iannaccone et al. "Pluripotent Embryonic Stem Cells From the Rat Are Capable of 29 Producing Chimeras", Developmental Biology, 163: 288-292, 1994. Kim et al. "Preparation of Multivesicular Liposomes", Biochimica et Biophysica 30 Acta, 728: 339-348, 1983. 31 Koutsourakis et al. "The Transcription Factor GATA6 Is Essential for Early Extraembryonic Development", Development, 126: 723-732, 1999. 32 Lee et al. "Recognition of Liposomes by Cells: In Vitro Binding and Endocytosis Mediated by Specific Lipid Headgroups and Surface Charge Density", Biochimica et Biophysica Acta, 1103: 185-197, 1992. Examiner Date

Considered

Signature

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number 10/559,929 INFORMATION DISCLOSURE Filing Date May 2, 2006 STATEMENT BY APPLICANT Peter LONAI Z"L First Named Inventor 1632 Art Unit (use as many sheets as necessary) Not Yet available Examiner Name 30800 Attorney Docket Number Of 6 Sheet OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), Initials* T² publisher, city and/or country where published. 33 Li et al. "Fibroblast Growth Factor Signaling and Basement Membrane Assembly Are Connected During Epithelial Morphogenesis of the Embryoid Body", The Journal of Cell Biology, 153(4): 811-822, 2001. Liu et al. "Role of Liposome Size and RES Blockade in Controlling Biodistribution 34 and Tumor Uptake of GM1-Containing Liposomes", Biochimica et Biophysica Acta, 1104: 95-101, 1992. Lo et al. "High Level Expression and Secretion of Fc-X Fusion Proteins in 35 Mammalian Cells", Protein Engineering, 11(6): 495-500, 1998. 36 Lodie et al. "Systematic Analysis of Reportedly Distinct Populations of Multipotent Bone Marrow-Derived Stem Cells Reveals A Lack of Distinction", Tissue Engineering, 8(5): 739-751, 2002. Martin et al. "The Development of Cystic Embryoid Bodies In Vitro From Clonal 37 Teratocarcinoma Stem Cells", Developmental Biology, 61: 230-244, 1977. Mitalipova et al. "Pluripotency of Bovine Embryonic Cell Line Derived From 38 Precompacting Embryos", Cloning, 3(2): 59-67, 2001. Mizushima et al. "PEF-BOS, A Powerful Mammalian Expression Vector", Nucleic 39 Acids Research, 18(17): 5322, 1990. 40 Molkentin "The Zinc Finger-Containing Transcription Factors GATA-4, -5, and -6", The Journal of Biological Chemistry, 275(50): 38949-38952, 2000. Morrisey et al. "GATA-4 Acitvates Transcription Via Two Novel Domains That 41 Are Conserved Within the GATA-4/5/6 Subfamily", The Journal of Biological Chemistry, 272(13): 8515-8524, 1997. Morrisey et al. "GATA6 Regulates HNF4 and Is Required for Differentiation of 42 Visceral Endoderm in the Mouse Embryo", Genes & Development, 12: 3579-3590, Namiki et al. "Intracellular Delivery of Glutathione S-Transferase Into Mammalian 43 Cells", Biochemical and Biophysical Research Communications, 305: 592-597, 2003. Notarianni et al. "Derivation of Pluripotent, Embryonic Cell Lines From the Pig and 44 Sheep", Journals of Reproduction & Fertility, Supplement 43: 255-260, 1991. 45 O'Brien et al. "Rac1 Orientates Epithelial Apical Polarity Through Effects on

Basolateral Laminin Assembly", Nature Cell Biology, Nature Cell Biology, 3: 831-

Date

Considered

Examiner

Signature

838, 2001.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Under the P	aperwork_Reduction A	Act of 199	o, no persons are requi	Complete if Known								
	Su	bstitute for form 1449	A/PTO		Application Number								
IN	FORM.	ATION DI	SCL	DSURE	Filing Date	Filing Date May 2, 2006							
ST	ATEM	ENT BY A	PPL	CANT	First Named Invento	or	Peter LONAI Z"L						
	6400 00	many sheets as	naaan	amı)	Art Unit								
	(use as	many sneets as	necess	ury)									
				<u> </u>	Examiner Name		Not Yet available						
Sheet		5	Of	6	Attorney Docket Nu		30800						
	1				TENT LITERATURE			<u></u>					
Examiner Initials*	Cite No.			oumal, serial sympo	ETTERS), title of the article osium, catalog, etc.) date, pa and/or country where publish	ge(s), volum			T²				
	46 Okabe et al. "Development of Neuronal Precursor Cells and Functional Postmitotic												
		Neurons From Embryonic Stem Cells In Vitro", Mechanisms of Development, 59:											
	89-102, 1996.												
	47	Passier et al. "Origin and Use of Embryonic and Adult Stem Cells in Differentiation											
		and Tissue Repair", Cardiovascular Research, 58: 324-335, 2003.											
	48	Reubinoff et	al. "Ne	ural Progenitors	s From Human Embryo	nic Stem (Cells", Na	ture					
		Biotechnology, 19: 1134-1140, 2001.											
	49	Rizzino et al. "Growth and Differentiation of Embryonal Carcinoma Cell Line F9 in Defined Media", Proc. Natl. Acad. Sci. USA, 77(1): 457-461, 1980.											
	50	Simpson et al. "Genetic Variation Among 129 Substrains and Its Importance for Targeted Mutagenesis in Mice", Nature Genetics, 16: 19-27, 1997.											
	51	Studier et al. "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes",											
		Methods in I	Methods in Enzymology, 185(Chap.6): 60-89, 1990.										
	52	Takamatsu et al. "Expression of Bacterial Chloramphenicol Acetyltransferase Gene											
		in Tobacco Plants Mediated by TMV-RNA", The EMBO Journal, 6(2): 307-311,											
		1987.			17.1001								
	53	Taylor et al. "Delivery of Bioactive, Gel-Isolated Proteins Into Live Cells",											
				1331-1337, 200									
	54				Protein That Changes	Color Wit	th Time",						
		Science, 290	: 1585-	1588, 2000.									
	55	Thomson et al. "Embryonic Stem Cell Lines Derived From Human Blastocysts",											
		Science, 282											
	56				ate Embryonic Stem C	ell Line",	Proc. Natl	l.					
				7844-7848, 19									
	57	Thomson et al. "Pluripotent Cell Lines Derived From Common Marmoset											
		(Callithrix Ja	icchus)	Blastocysts", B	iology of Reproduction	ı, 55: 254-	259, <u>1996</u>	5.					
	58	Thomson et al. "Primate Embryonic Stem Cells", Current Topics in Developmental											
	59	Biology, 138: 133-165, 1998. Wang et al. "Highly Efficient DNA Delivery Mediated by PH-Sensitive											
	39	Immunoliposomes", Biochemistry, 28: 9508-9514, 1989.											
	60	Wheeler "Development and Validation of Swine Embryonic Stem Cells: A											
	00				d Development, 6: 563-								
Examiner	-	i itoriow , ito	produc	I Ordiney dire	- 2010iopinoni, 0. 303	Date	<u>- </u>						
C' .						Date		1					

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Considered

Signature

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/559,929 INFORMATION DISCLOSURE Filing Date May 2, 2006 STATEMENT BY APPLICANT First Named Inventor Peter LONAI Z"L Art Unit 1632 (use as many sheets as necessary) Examiner Name Not Yet available 6 Attorney Docket Number 30800 Of 6 Sheet OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite Initials* No. item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. T² 61 Zhang et al. "In Vitro Differentiation of Transplantable Neural Precursors From Human Embryonic Stem Cells", Nature Biotechnology, 19: 1129-1133, 2001.

Examiner	Date	
Signature	Considered	_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.